http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114042154-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49c2028bfc767e6685a5dd6029b3ddc7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2021-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92db986e937b90d9518b4d3b7594593b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aca87e723368aee8785604c10aec966c |
| publicationDate | 2022-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114042154-A |
| titleOfInvention | Application of medicine composition in preparing anti-tumor combination therapy medicine |
| abstract | The invention discloses application of a drug combination in preparation of an anti-tumor combination therapy drug, and relates to the technical field of biological medicines. The medicine composition comprises: polypeptides and/or antibodies that inhibit PD-1 or inhibit PD-L1, and traditional Chinese medicine components; the Chinese medicinal component is lycorine or its salt, or its hydrate. The inventor finds that the traditional Chinese medicine component lycorine jointly inhibits PD-1 or inhibits polypeptide and/or antibody of PD-L1 to obtain a synergistic antitumor effect in vivo and obviously improves the immune microenvironment. This provides a favorable premise for preparing anti-tumor combination therapy medicines, and also provides a potential strategy for jointly enhancing the PD-1/PD-L1 antibody. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114533884-A |
| priorityDate | 2021-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.